For companies like GSS, it seems that a rule of thumb applies where the global revenue tends to be 20x Australian revenue. With the current product maturity level, this implies a prospective global revenue of ~100m if FDA approval is forthcoming. That would put a real rocket under the market.
- Forums
- ASX - By Stock
- GSS upside potential
GSS
genetic signatures limited
Add to My Watchlist
0.00%
!
36.5¢

For companies like GSS, it seems that a rule of thumb applies...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.90M |
Open | High | Low | Value | Volume |
36.5¢ | 36.5¢ | 36.5¢ | $657 | 1.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11082 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 45991 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11082 | 0.365 |
3 | 10907 | 0.360 |
4 | 130509 | 0.350 |
1 | 1683 | 0.300 |
1 | 25000 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 45991 | 2 |
0.390 | 20000 | 1 |
0.400 | 111918 | 2 |
0.420 | 40000 | 2 |
0.455 | 5000 | 1 |
Last trade - 10.22am 08/07/2025 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |